Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib in HER2-positive Early Breast Cancer (PYHOPE-BC-104)
NCT04717531Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2021
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in HER2-positive breast cancer, sponsored by Jiangsu Provincial People's Hospital. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04717531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04717531.